Sponsor-Investigators more likely to receive FDA warnings

Blair Holbein, Ph.D., Assistant Professor of Clinical Science and a core expert in the Center for Translational Medicine, was co-author of "Warning Letters to Sponsor-Investigators at Academic Health Centres – The Regulatory 'Canaries in a Coal Mine."

The study findings suggest that sponsor-Investigators receive FDA warning letters more often than other types of investigators, usually due to a lack of monitoring.